CIP
ISEE

Convergence Investment Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Convergence Investment Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-42,370
Closed -$2.21M – 428
2015
Q2 		$2.21M Buy
+42,370
New +$2.11M 0.22% 154

Other funds holding ISEE

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Convergence Investment Partners's ISEE Position: Q3 2015 in Review

Convergence Investment Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2015, closing a stake of 42,370 shares — an estimated $2.21M sold.

Convergence Investment Partners first reported a position in ISEE in Q2 2015 and held it in 1 quarter. The position peaked at $2.21M in Q2 2015. 144 funds tracked by Wall St. Rank hold ISEE as of Q3 2015.

  • Convergence Investment Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Convergence Investment Partners sold 42,370 IVERIC bio, Inc. Common Stock shares in Q3 2015, an estimated $2.21M.
  • Convergence Investment Partners first reported a position in IVERIC bio, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Convergence Investment Partners's IVERIC bio, Inc. Common Stock position peaked at $2.21M in Q2 2015.
  • 144 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2015.

Based on Convergence Investment Partners's 13F filing for Q3 2015, filed 16 Nov 2015.